HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.
HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.